



**PANCREATIC  
CANCER**

**A medical and public  
health emergency**

***Alfredo Carrato. Ramon y Cajal University Hospital. Madrid***


# Further work and investment in medical research is still required to diminish the burden of cancer and improve patient survival

- Máire Geoghegan-Quinn, EU Commissioner for Research and Innovation

## Cancer's Challenge for Europe

Cancer is everybody's business. In 2012 alone, 3.2 million people in Europe were diagnosed for the first time with cancer, about 13 million people were affected and 1.2 million died from this disease.

**103.845 patients**  
affected by  
pancreatic cancer  
in Europe<sup>23</sup>




11. European Cancer Organisation. Oncopolicy Forum 2012 Report. <http://www.ecco-org.eu/Public-affairs/Oncopolicy-Forum-and-Events/Oncopolicy-forum/2012.aspx>  
23. Globocan/IARC factsheet 2012: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_population.aspx](http://globocan.iarc.fr/Pages/fact_sheets_population.aspx) [accessed Oct 2014]

# Pancreatic cancer is the only cancer where mortality rates are increasing for both sexes

Pancreatic cancer is currently the 4th biggest cause of mortality in cancer in Europe<sup>12</sup>

European mortality rates of pancreatic cancer compared with other diseases<sup>12</sup>




12.. Malvezzi 2014. Annals of Oncology. European cancer mortality predictions for the year 2014

25. Pancreatic Cancer Action Network. The alarming rise of pancreatic cancer deaths in The United States: Why we need to stem the tide today, 2012.

[www.pancan.org/wp-content/uploads/2013/01/incidence\\_report\\_2012\\_executive\\_summary.pdf](http://www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012_executive_summary.pdf) [Last accessed April 2014]

# Pancreatic cancer will be responsible for more deaths than breast cancer by 2020

US mortality rates of pancreatic cancer compared with other cancers<sup>25</sup>







25. Pancreatic Cancer Action Network. The alarming rise of pancreatic cancer deaths in The United States: Why we need to stem the tide today, 2012. [www.pancan.org/wp-content/uploads/2013/01/incidence\\_report\\_2012\\_executive\\_summary.pdf](http://www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012_executive_summary.pdf) [Last accessed April 2014]

# Incidence & mortality of pancreatic cancer in Spain

**CANCER INCIDENCE<sup>1</sup>**  
BOTH SEXES (% of total)

**CANCER-RELATED MORTALITY<sup>1</sup>**  
BOTH SEXES (% of total)




**PaCa INDICENCE IS LOW AND MORTALITY RATES ARE HIGH**

- **Incidence** of PaCa is relatively **low**:
  - In 2012, PaCa was **3% (6,367)** of new cancer cases in Spain, being the eight-most frequent cancer<sup>2</sup>
- **Mortality** rates are **high**:
  - In 2012, PaCa was the **fourth-leading cause of cancer-related death**<sup>3</sup>

1) "Las Cifras del Cáncer en España 2014" SEOM Sociedad Española Oncología Médica. Globocan 2012 (Online database) <http://globocan.iarc.fr/>

**The annual incidence and mortality of pancreatic cancer are the same, meaning that most people will die from the disease within one year**

Age-standardised incidence and mortality rates<sup>20</sup>



20. Globocan/IARC factsheet 2012: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_population.aspx](http://globocan.iarc.fr/Pages/fact_sheets_population.aspx) [accessed Sept 2014]

Note: ASR: Age-standardised rate (weighted)

# The vast majority of people will die within 5 years of diagnosis


**1-year survival**  
~ 20%

Based on a recent EU literature review of observational studies, 1-year survival rates of pancreatic cancer patients ranged between 10% and 23%, with the largest study reporting a survival rate of 16%<sup>15</sup>

**5-year survival**  
~5%

Overall 5-year survival rates ranged from 0.5% to 9% based on an EU literature review of real-world evidence with the two largest studies reporting 5% and 3%<sup>15</sup>

## US 5-year survival rates of various cancers<sup>22</sup>



5-year survival for pancreatic cancer is dismal and one of the lowest of all cancers

15. Carrato A, Falcone A, Ducreux M, Valle J, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I. A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality-of-life, and costs. *J Gastrointest Cancer* 2015 Sep;46(3):201-11

22. NCI SEER factsheet: <http://seer.cancer.gov/statfacts/html/pancreas.html>

# Pancreatic adenocarcinoma statistics

- High recurrence rates after surgery (75%), usually in the first year
- Prevention must be a primary strategy target
- 5-year overall survival:
  - All Stages (7%), Local (26%), Regional (10%), Distant (2%)

<b>Stage</b>	<b>Percentage of patients at diagnosis</b>	<b>Median overall survival, months</b>
Metastatic	50	6-9
Locally advanced	30-35	9-12
Resectable	15-20	15-20

# Delays in diagnosis & treatment are common and have a potentially large impact on overall survival

- Symptom → HCP contact = 30 days (1-1460 day range)
- HCP → tissue diagnosis = 35 days (1-365 day range)
- Diagnosis → treatment = 21 days (0-120 day range)
- **Median delay = 4 months** (112 days)
- 25/134 patients (19%) had ≥ 6 months delay
- Delay per stage:

This magnitude of delay represents a significant fraction of overall survival for many pancreatic cancer patients

Pancreatic Cancer Stage	Number of Patients	Delays, days	Range, days
Resectable (Stage I/II)	46	82	20-1610
Locally advanced (Stage III)	40	141	42-448
Metastatic (Stage IV)	48	117	46-436


# Pancreatic cancer today

- After surgery (20% patients), adjuvant therapy works. Gemcitabine and 5-FU/leucovorin have similar effects
- Several 1st and a 2<sup>nd</sup> line chemotherapy treatment options for locally advanced and metastatic disease are recently available
- Stromal associated targets, especially immune targets, are being addressed
- Robust **research** efforts underway to **personalized treatment** and well designed **clinical & translational trials** should be offered to the patient
- **Prevention** must be a primary strategy target, either primary or screening
- **Awareness:** It could change from being a death sentence, if it can be **diagnosed early enough**

# A recent global survey showed that pancreatic cancer is virtually unknown by many in Europe



DESIRE FOR GREATER PUBLIC AWARENESS





# Conoce los 10 signos

Cáncer de Páncreas



Depresión



Signos de ictericia



Náuseas



Pérdida de peso inexplicada



Dolor abdominal



Cambios en el hábito intestinal: diarrea



Dolor en la parte media de la espalda



Cambios en el hábito intestinal: esteatorrea



Diabetes de nueva aparición no asociada a aumento de peso



Trombosis venosa profunda

 Si experimenta de manera continuada dos o más de estos síntomas, y no son normales para usted, debe consultar a su médico de Atención Primaria ya que pueden indicar Cáncer de Páncreas.





# ¡Piensa en **cáncer de páncreas!**

*¡Piense antes en el Cáncer de Páncreas! El Cáncer de Páncreas es actualmente la cuarta causa de muerte por Cáncer. Si no hay mejoras en el diagnóstico, se espera que se convierta en la segunda causa de muerte por Cáncer en el año 2020.*

## Cuándo enviar un paciente a un especialista?

### 1. Factores de riesgo y antecedentes médicos

- **Población mayor de 50 años** (existen también pacientes más jóvenes)
- **Diabetes no asociada al aumento de peso**
- **Fumador**
- **Consumo de alcohol habitual**
- **Obesidad:** IMC mayor o igual a 25
- **Antecedentes:** El riesgo aumenta si el paciente ha padecido:
  - Cáncer
  - Enfermedades gastrointestinales inflamatorias
  - Antecedentes hereditarios de Cáncer familiar
  - Pancreatitis crónica
  - Pancreatitis hereditaria
- **Historia familiar:** acientes con al menos 2 familiares de primer grado diagnosticados con Cáncer de Páncreas

### 2. ¿Su paciente ha experimentado alguno de los siguientes síntomas?

A continuación encontrará los síntomas clave para orientar el diagnóstico de Cáncer de Páncreas en sus pacientes.

- |  |  |
|--|--|
|  Signos de ictericia  |  Cambios en el hábito intestinal: diarrea     |
|  Náuseas  |  Cambios en el hábito intestinal: esteatorrea |
|  Dolor en la parte media de la espalda                      |  Dolor abdominal                              |
|  Pérdida de peso inexplicada                                |  Trombosis venosa profunda                    |
|  Diabetes de nueva aparición no asociada al aumento de peso |  Depresión                                    |

**Si su paciente presenta dos o más factores de riesgo y alguno de los síntomas enunciados, debe valorar si se trata de un Cáncer de Páncreas.**

Pancreatic cancer **registries** will identify areas for improvement



# Impact & potential of PancreOS

**A solid data base** for obtaining regular information on the burden and clinical management of pancreatic cancer in the European countries

**A reference platform** for every professional involved in epidemiology, research and management of pancreatic cancer



**Large amount of information available** related to “all aspects” of the management of patients with pancreatic cancer – from initial symptoms, diagnosis and throughout the treatment continuum



**Valuable to increase our knowledge** on the biology of pancreatic cancer tumors, to identify high-risk subgroups and to customize treatment

The data provided by PancreOS would be used:

- To obtain an updated description of trends on pancreatic cancer survival and information on the differences observed between centres and countries.
- To identify areas of improvement
  - Earlier & accurate diagnosis
  - Biobanks creation
  - High-risk groups identification, screening programs implem.
  - Improve translational & clinical research for tailor-made treatments
  - Centres of excellence accreditation, etc.
- To study the patterns of prevention, diagnosis, treatment and subsequent outcomes



# Pancreatic cancer Registry: PancreOS Europe and the pilot study in Spain

**Population:** Hospital-based patients with pancreatic cancer at any stage.

**Study Design:** Prospective

## Primary Objective:

To correlate overall survival (OS), the biological behavior of the tumor, and the resources used for the diagnosis and treatment of pancreatic cancer (in Spain and later on, in Europe) in order to identify areas of improvement for the benefit of our patients.

**Stage I-Pilot in Spain**  
*7 centers*



**50-70 patients (estimation)**  
Period of time: 4 months

**Stage 2- Registry in Spain**  
*15 centers*  
**600 patients (estimation)**  
Period of time: up to 3 years



Red Española de Registros de Cáncer



ENCR  
European Network  
of Cancer Registries



**PancreOS**  
PANCREATIC CANCER OVERALL SURVIVAL REGISTRY  
EUROPE


**Stage 2- Registry in Europe**  
*Several countries*  
**600 patients/country (estimation)**  
Period of time: up to 3 years



# Cancer research funding: Unlike other cancers, pancreatic cancer outcomes have not significantly benefited<sup>28</sup>


## Cancer research investments in the UK<sup>28</sup>

5-year survival rates in the UK in 2005-2009<sup>28</sup>




Investments in cancer research in the UK doubled within a decade, however unlike other cancers, pancreatic cancer outcomes have not yet benefited from these investments<sup>28</sup>

# NATIONAL CANCER INSTITUTE FUNDING



# To address the high disease burden, pancreatic cancer should be a research priority involving multiple stakeholders

- Pancreatic cancer research needs to be a multi-stakeholder effort




# Pancreatic Cancer patients need to have the same opportunities as other cancer patients



*“I dream that the word ‘cure’ will no longer be followed by the words ‘it's impossible’”*

Patrick Swayze,  
died from pancreatic cancer



*“The most important thing is to never lose hope, to never get depressed [....]  
I am afraid of leaving my sons and wife alone”*

Anonymous pancreatic cancer patient

# Pancreatic Cancer patients need to have the same opportunities as other cancer patients



Luciano Pavarotti



Alfredo Kraus



Rocío Jurado



# A call to actions

